NCT06712472 - Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer | Biotech Hunter

Enrollment

554

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

June 30, 2030

Study Completion Date

December 31, 2031

Conditions

Endometrial CancerP53abn

Interventions

DRUG

Olaparib (300 mg BID)

Olaparib 300mg Bid during one year.

Trial Locations (15)

11000

RECRUITING

Centre Hospitalier de Carcassonne, Carcassonne

13009

RECRUITING

Institut Paoli Calmettes, Marseille

21000

RECRUITING

Chu Dijon, Dijon

25030

RECRUITING

Chu Besancon, Besançon

38000

NOT_YET_RECRUITING

Groupe Hospitalier Mutualiste de Grenoble, Grenoble

44800

RECRUITING

INSTITUT CANCEROLOGIE DE L'OUEST-St HERBLAIN, Saint-Herblain

49055

RECRUITING

Institut Cancerologie de L'Ouest-Angers, Angers

67000

RECRUITING

Clinique Sainte Anne, Strasbourg

69008

RECRUITING

Centre LEON BERARD, Lyon

75005

RECRUITING

Institut Marie-Curie, Paris

75014

NOT_YET_RECRUITING

Hopital Cochin, Paris

81000

RECRUITING

Centre Hospitalier D'Albi, Albi

87000

RECRUITING

CHU De LIMOGES, Limoges

94805

RECRUITING

Gustave Roussy, Villejuif

06189

RECRUITING

Centre Antoine LACASSAGNE, Nice